In an AD cell model, galangin treatment was shown to inhibit the expression of BECN1 and p-GSK3β but promote autophagy and decrease levels of Aβ and p-Tau by regulating the AKT/GSK3β/mTOR pathway. Here, MAPT is linked to Alzheimer disease.